Evaluation of the diabetes care cascade and compliance with WHO global coverage targets in Iran based on STEPS survey 2021

Azadnajafabad, Sina; Ahmadi, Naser; Rezaei, Negar; Rashidi, Mohammad-Mahdi; Saeedi Moghaddam, Sahar; Mohammadi, Esmaeil; Abbasi-Kangevari, Mohsen; Naderian, Mohammadreza; Ghasemi, Erfan; Farzi, Yosef; Kazemi, Ameneh; Dilmaghani-Marand, Arezou; Yoosefi, Moein; Rezaei, Shahabeddin; Nasserinejad, Maryam; Fattahi, Nima; Rezaei, Nazila; Haghshenas, Rosa; Foroutan Mehr, Elmira; Koolaji, Sogol; Razi, Farideh; Djalalinia, Shirin; Larijani, Bagher; Farzadfar, Farshad

Evaluation of the diabetes care cascade and compliance with WHO global coverage targets in Iran based on STEPS survey 2021

Sina Azadnajafabad, Naser Ahmadi, Negar Rezaei, Mohammad-Mahdi Rashidi, Sahar Saeedi Moghaddam, Esmaeil Mohammadi, Mohsen Abbasi-Kangevari, Mohammadreza Naderian, Erfan Ghasemi, Yosef Farzi, Ameneh Kazemi, Arezou Dilmaghani-Marand, Moein Yoosefi, Shahabeddin Rezaei, Maryam Nasserinejad, Nima Fattahi, Nazila Rezaei, Rosa Haghshenas, Elmira Foroutan Mehr, Sogol Koolaji, Farideh Razi, Shirin Djalalinia, Bagher Larijani and Farshad Farzadfar

Open Access Publications from Kiel Institute for the World Economy from Kiel Institute for the World Economy (IfW Kiel)

Abstract: This study aimed to investigate the diabetes mellitus (DM) and prediabetes epidemiology, care cascade, and compliance with global coverage targets. We recruited the results of the nationally representative Iran STEPS Survey 2021. Diabetes and prediabetes were two main outcomes. Diabetes awareness, treatment coverage, and glycemic control were calculated for all population with diabetes to investigate the care cascade. Four global coverage targets for diabetes developed by the World Health Organization were adopted to assess the DM diagnosis and control status. Among 18,119 participants, the national prevalence of DM and prediabetes were 14.2% (95% confidence interval 13.4–14.9) and 24.8% (23.9–25.7), respectively. The prevalence of DM treatment coverage was 65.0% (62.4–67.7), while the prevalence of good (HbA1C

Date: 2023
New Economics Papers: this item is included in nep-ara and nep-inv
References: View complete reference list from CitEc
Citations:

Downloads: (external link)
https://www.econstor.eu/bitstream/10419/279316/1/s41598-023-39433-7.pdf (application/pdf)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:zbw:ifwkie:279316

DOI: 10.1038/s41598-023-39433-7

Access Statistics for this paper

More papers in Open Access Publications from Kiel Institute for the World Economy from Kiel Institute for the World Economy (IfW Kiel) Contact information at EDIRC.
Bibliographic data for series maintained by ZBW - Leibniz Information Centre for Economics ().